Pae Chi-Un, Kim Yoo-Jin, Won Wang-Youn, Kim Hee-Je, Lee Seok, Lee Chang-Uk, Lee Soo-Jung, Kim Dong-Wook, Lee Chul, Min Woo-Sung, Kim Chun-Choo, Paik In-Ho, Serretti Alessandro
Department of Psychiatry, Kangnam St Mary's Hospital, The Catholic University of Korea College of Medicine, 505 Banpo-Dong, Seocho-Gu, Seoul, 137-701, Korea.
Hum Psychopharmacol. 2004 Jan;19(1):25-9. doi: 10.1002/hup.541.
The efficacy and tolerability of paroxetine in the treatment of depressive disorders is well known, however, its efficacy and safety for the treatment of depression in patients with cancer has been poorly studied. Therefore this study was aimed at evaluating the efficacy and tolerability of paroxetine in the treatment of depressed patients with haematological malignancy (HM).
Fifty-two patients with major depressive disorder (MDD) based on DSM-IV criteria along with comorbid HM were allotted to an 8 week trial with a flexible-dose regime of paroxetine in combination with their chemotherapy or supportive pharmacotherapy. The treatment response was assessed at baseline, week 2, week 4 and week 8 with the 17-item Hamilton rating scale for depression (HAM-D17), the Montgomery Asberg depression rating scale (MADRS) and the clinical global impression-severity (CGI-S). Side effects were collected with reported adverse events and laboratory tests throughout the study period.
44.2% of 52 patients completed the 8 week trial. Scores on the HAM-D17, MADRS and CGI-s (last observation carried forward, LOCF) at baseline were significantly reduced with a mean reduction of 30.5%, 32.8% and 39.1%, respectively, after 8 weeks treatment with paroxetine.
In this preliminary study, paroxetine was found to be effective and moderately tolerated in the treatment of depressed patients with HM, and the present study calls for a controlled study in this field to extend and form a framework on the psychopharmacological data in this field.
帕罗西汀治疗抑郁症的疗效和耐受性已为人熟知，然而，其治疗癌症患者抑郁症的疗效和安全性却鲜有研究。因此，本研究旨在评估帕罗西汀治疗血液系统恶性肿瘤（HM）伴发抑郁症患者的疗效和耐受性。
52例符合DSM-IV标准的重度抑郁症（MDD）合并HM的患者被分配至一项为期8周的试验，采用帕罗西汀灵活剂量方案联合化疗或支持性药物治疗。在基线、第2周、第4周和第8周，使用17项汉密尔顿抑郁量表（HAM-D17）、蒙哥马利-阿斯伯格抑郁量表（MADRS）和临床总体印象-严重程度（CGI-S）评估治疗反应。在整个研究期间，通过报告的不良事件和实验室检查收集副作用。
52例患者中有44.2%完成了8周试验。帕罗西汀治疗8周后，基线时HAM-D17、MADRS和CGI-S（末次观察向前结转，LOCF）评分显著降低，平均降低分别为30.5%、32.8%和39.1%。
在这项初步研究中，发现帕罗西汀治疗HM伴发抑郁症患者有效且耐受性中等，本研究呼吁在该领域开展对照研究，以扩展并形成该领域心理药理学数据的框架。
